The US Food and Drug Administration has confirmed 180 days of generic market exclusivity for Eagle Pharmaceuticals’ generic to Par’s Vasostrict (vasopressin) 20 units/ml injectable, allowing for a tentative approval to be handed to Amphastar Pharmaceuticals for its Vasostrict ANDA product.
New Jersey-based Eagle has now confirmed it will begin shipping its vasopressin product on 17 January 2022, ahead of launching its Pemfexy (pemetrexed)